S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be an
effective treatment for myelodysplastic syndrome.
PURPOSE: Phase II trial to study the effectiveness of antithymocyte globulin plus
cyclosporine in treating patients who have myelodysplastic syndrome.